Sensitivity and Specificity of Non-Invasive Blood Glucose Level Measurement Optical Device to Detect Hypoglycaemia

Renan Prasta JENIE1,2,3,*, Naufal Muharam NURDIN2, Iرزaman HUSEIN1,* and Husin ALATAS1

1 Physics Department, Mathematics and Natural Sciences Faculty, IPB University, Babakan, Dramaga, Bogor, West Java, Indonesia 16680
2 Community Nutrition Department, Human Ecology Faculty, IPB University, Babakan, Dramaga, Bogor, West Java, Indonesia 16680
3 Public Health Department, Public Health Faculty, Binawan University, East Jakarta, Jakarta, Indonesia 13630

(Received June 13, 2019)

Summary Hypoglycemia is related to lethargy, psychiatric disorders, and impaired brain metabolism. Hypoglycemia is one of the leading factors of death in blood glucose level (BGL) metabolism disorders. Optical methods have been heavily researched due to its potential to eliminate drawbacks of conventional hypoglycemia detection; however, clinical data are still scarce. This study objective was to measure the sensitivity and specificity of non-invasive BGL Measurement Optical Device (NI-BGL-MOD) to detect hypoglycemia. The reference standard is venipuncture spectrophotometry. Researcher has developed NI-BGL-MOD, which we have used in a clinical trial in December 2015. The researchers have used spectral data collected from the device to measure the BGL of randomly selected 110 participants who were older than 17 y old. Each participant was measured five times. There are a total of 550 data sets that were then compared to BGL measurement using the reference standard. The spectral data were optimized using Discrete Fourier Transform and inferred to BGL prediction using the Fast Artificial Neural Network. Researchers have defined hypoglycemia case with BGL level at 75 mg/dL or lower. The researchers have calculated sensitivity and specificity using epiR in Rstudio. Respondents’ BGL values were between 67 to 96 mg/dL. Researchers have classified eighty-nine cases as hypoglycemia. There are 461 cases classified as not hypoglycemia. The sensitivity was 54%, and the specificity was 97%. Diagnostic accuracy was 86%, and the number to diagnose was 1.96. The newly developed method NI-BGL-MOD could be used to detect hypoglycemia.

Key Words non-invasive, blood glucose level, measurement, optical device, hypoglycemia

Hypoglycaemia is a state of decreased blood glucose level (BGL) or concentration in human blood (1). Hypoglycaemia is related to lethargy (2), psychiatric disorders (3), and impaired brain metabolism (4).

Hypoglycaemia is one of the leading factors of death in BGL metabolism disorders. Patients experiencing severe hypoglycaemia were at higher risk of CV events and death. The risk particularly high shortly after the hypoglycemic episode (5). Recurrent induced hypoglycaemia may cause severe hypoglycaemia. Other related risks include hypoglycemic arrhythmic death and vascular diseases (6). Hypoglycaemia mediated effects may contribute to cardiovascular dysfunction. Hypoglycaemia could cause Qt interval prolongation. Hypoglycaemia related to increased plasma epinephrine and norepinephrine concentrations. Hypoglycaemia related to hypokalemia. Hypoglycaemia related to changes to cardiac workload and heart rate. Hypoglycaemia may cause a fall in central arterial pressure and large vessel elasticity. Hypoglycaemia related to an increase in endothelial dysfunction and inflammation. Hypoglycaemia related to platelet aggregation and increased blood coagulation (7).

BGL measurement is an integral part of nutritional management. Currently, there are no known dependable methods to detect hypoglycaemia and giving a warning system to the patient. Hypoglycaemia can only predict from its a symptom, or measured using conventional blood glucose level measurement. The methods itself based on phlebotomy or blood extraction procedure, which is hurting, risk of disease spread, need skilled person, and relatively costly (8). The only currently plausible methods to detect hypoglycaemia is using the Continuous Glucose Monitoring System, which is not portable and costly (9, 10).

Optical methods have been heavily researched due to its potential to eliminate drawbacks of conventional hypoglycaemia detection; however, clinical data are still scarce (11, 12). The researcher has done a clinical trial of non-invasive methods to non-invasively measure the blood glucose level in 2016 (13, 14). Then the
Researcher realises the possibility of using the same methods to detect the hypoglycaemia. This study objective was to measure the sensitivity and specificity of non-invasive BGL Measurement Optical Device (NI-BGL-MOD) to detect hypoglycaemia. The researchers have used venipuncture spectrophotometry as a reference standard.

**MATERIALS AND METHODS**

This research is an experimental research using secondary data taken from a previous clinical trial of NI-BGL-MOD (15, 16). Researcher team have designed the NI-BGL-MOD in 2015 (13, 14). The Clinical team did the clinical trial in December 2015, and the team has done the data analysis in 2018. The research team has registered the clinical trial to Health Research Ethical Committee, National Institute of Health Research and Development, Indonesian Ministry of Health; no LB.02.01/5.2/KE.493/2016).

The researchers have used spectral data collected from the device to measure the BGL of 110 participants. Participants were older than 17 y old, did not tire, having alcoholic drinks, smoking, nor pregnant. Each participant was measured five times. Five hundred fifty data sets compared to BGL measurement using reference standard.

The spectral data were optimized using Discrete Fourier Transform (17) and inferred to blood glucose level prediction using Fast Artificial Neural Network (18). The researcher has defined hypoglycaemia case with BGL level at 75 mg/dL or lower (1). The researchers have calculated sensitivity and Specificity (19) using epiR (20) in Rstudio (21).

**RESULTS**

Respondents’ BGL values were between 67 to 96 mg/dL. The researchers have classified Eighty-nine cases as hypoglycaemia. Four hundred sixty-one cases have classified as not hypoglycaemia (Table 1).

The sensitivity was 54%, and the specificity was 97%. Diagnostic accuracy was 86%, and the number to diagnose was 1.96 (Table 2).

**DISCUSSION**

NI-BGL-MOD Specificity at 97% shows that practitioner may use NI-BGL-MOD method for detecting hypoglycaemia. However, sensitivity at 54% leaves room for further improvement.

Current methods for detecting hypoglycaemia using apparent clinical symptom observation, like using dogs (22), still outdone NI-BGL-MOD methods in the substantial margin at the specificity of 97.5%, and sensitivity of 100% (23, 24). Periodical data observation dependent methods such as statistical methods (25, 26) and machine learning-based methods (27, 28) gave a comparable performance to our methods (Table 3).

The number needed to diagnose at 1.96 means at a minimum, only two repeated measurements needed

### Table 1. Base prevalence of hypoglycaemia. Hypoglycaemia detected using NI-BGL-MOD. The value then compared to venipuncture measurement.

| NI BGL MOD   | Positive Hypoglycaemia | Negative Hypoglycaemia | Total |
|--------------|------------------------|------------------------|-------|
| Positive Hypoglycaemia | 78 | 11 | 89 |
| Negative Hypoglycaemia | 67 | 394 | 461 |
| Total | 145 | 405 | 550 |

### Table 2. Sensitivity and specificity of NI-BGL-MOD for hypoglycaemia detection.

| Parameters                                      | Estimation | Lower | Upper |
|-------------------------------------------------|------------|-------|-------|
| Apparent Prevalence                             | 0.162      | 0.132 | 0.195 |
| True Prevalence                                 | 0.264      | 0.227 | 0.303 |
| Sensitivity                                      | 0.538      | 0.453 | 0.621 |
| Specificity                                      | 0.973      | 0.952 | 0.986 |
| Diagnostic Accuracy                              | 0.858      | 0.826 | 0.886 |
| Diagnostic Odd Ratio                            | 41.7       | 21.1  | 82.5  |
| Number Needed to Diagnose                       | 1.958      | 1.646 | 2.468 |
| Youden Index                                     | 0.511      | 0.405 | 0.607 |
| Positive Predictive Value                       | 0.876      | 0.790 | 0.937 |
| Negative Predictive Value                       | 0.855      | 0.819 | 0.886 |
| Likelihood Ratio of a Positive Test             | 19.81      | 10.85 | 36.16 |
| Likelihood Ratio of a Negative Test             | 0.475      | 0.398 | 0.567 |

### Table 3. Comparison of sensitivity and specificity of methods to detect hypoglycaemia.

| Hypoglycaemic Detection Methods                  | Sensitivity | Specificity | Reference |
|-------------------------------------------------|-------------|-------------|-----------|
| NI-BGL MOD                                      | 54%         | 86%         | This trial|
| Measurable Biomarker                            | 89%         | 100%        | (23)      |
| Clinical Symptom Observation                    | 98%         | 92%         | (24)      |
| Statistical Data Observation                    | 84%         | 82%         | (25)      |
| Machine Learning Data Observation               | 78%         | 60%         | (29)      |
| Machine Learning Data Observation               | 80%         | 50%         | (30)      |
| Machine Learning Data Observation               | 80%         | 98%         | (28)      |
| Machine Learning Data Observation               | 69%         | 97%         | (27)      |
to diagnose hypoglycaemia accurately. The current designed NI-BGL-MOD is taking five measurements sequentially and take the average, which is sufficient.

NI-BGL-MOD eliminate the use of phlebotomy to extract human blood from the central vein or peripheral vein in conventional biomarker measurement method. NI-BGL-MOD make use of minimal human auditory capabilities to detect hypoglycaemia, as opposed to clinical symptom observation. NI-BGL-MOD rely on non-invasive measurement rather than observation of data series, as opposed to a statistical or machine-learning data-observation method (29, 30).

The current clinical trial data came from cross-sectional or one-time measurement data, as opposed to array periodical measurement, so. In contrast, the system designed to detect hypoglycaemia, further clinical trial needed to detect the timing for such instance. The current clinical trial data came from cross-sectional or one-time measurement data, as opposed to array periodical measurement, so. In contrast, the system designed to detect hypoglycaemia, further clinical trial needed to detect the timing for such instance.

Therefore, the artificial intelligence or machine learning engine is similar to those used on the periodical data observation method. However, the current system does not yet to have the capabilities to detect when the hypoglycaemic instance shall occur.

Based on the evidence shown from the current study, the researchers concluded that the newly developed method NI-BGL-MOD could be used to detect hypoglycaemia. Researchers are planning to conduct one further clinical trial in 2020. The trial shall use an oral glucose tolerance test setting (31, 32) to further elaborate NI-BGL-MOD methods potential for detecting hypoglycaemic event timing.

Disclosure of state of COI
The authors declare no competing interests.

Acknowledgments
This experimental study is supported by Hibah Pene-litian Dasar Unggulan Perguruan Tinggi (PDUPUT) Direktorat Jendral Penguatan Riset dan Pengembangan Kemenristekdikti Republik Indonesia under grant 3/E1/KPPTNKBH/2019, 29 March 2019.

REFERENCES
1) Goto A, Arah OA, Goto M, Teraruchi Y, Noda M. 2013. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347: f533.
2) Kumari A, Verma R, Bharti R. 2012. Dynamics of metabolism in Rana tigrina-A comparative biochemical study between blood glucose and serum cholesterol during summer and winter sleep. IOSR J Pharm Biol Sci 4: 43–44.
3) Kanahara N, Shimizu E, Iyo M, Sekine Y. 2012. Resting State Blood Flow and Glucose Metabolism in Psychiatric Disorders. INTECH Open Access Publisher.
4) Meierhans R, Béchir M, Ludwig S, Sommerfeld J, Brandi G, Haberthür C, Stocker R, Stover JF. 2010. Brain metabolism is significantly impaired at blood glucose below 6 mM and brain glucose below 1 mM in patients with severe traumatic brain injury. Critical Care 14: R13.
5) Zimman B, Marso SP, Christiansen E, Calanna S, Ramussen S, Buse JB, the LEADER Publication Committee on behalf of the LEADER Trial Investigators. 2018. Hypoglycemia, cardiovascular outcomes, and death: The LEADER experience. Diabetes Care 41: 1783–1791.
6) Cryer PE. 2015. Hypoglycemia-associated autonomic failure in diabetes: Maladaptive, adaptive, or both? Diabetes 64: 2322–2323.
7) Hanefeld M, Frier BM, Pistrosch F. 2016. Hypoglycemia and cardiovascular risk: Is there a major link? Diabetes Care 39: S205–S209.
8) The State of Queensland Health 2011. Adrenal Vein Sampling.
9) Siegmund T, Kolassu R, Thomas A. 2013. Clinical update on insulin pump therapy in combination with continuous glucose monitoring. Minerva Endocrinol 38: 133–143.
10) Cameron F, Buckingham BA, Wilson DM, Bequette BW. 2014. Sensitivity analysis of a predictive pump suspension system to treat people with type 1 diabetes. IFAC Proceeding Volumes 19: 243–248.
11) Srivastava A, Chowdhury MK, Sharma S, Sharma N. 2013. Blood glucose monitoring using non invasive optical method: Design limitations and challenges. International J Advanced Research in Electrical, Electronics and Instrumentation Engineering 2: 615–620.
12) Srivastava A, Chowdhury MK, Sharma S, Sharma N. 2013. Optical clearance effect determination of glucose by near infrared technique: An experimental study using an intralipid based tissue phantom. International J Advances in Engineering & Technology (IJASET) 6: 1097–1108.
13) Jenie RP, Iskandar J, Kurniawan A, Rustami E, Syaifutra H, Nurdin NM, Handoyo T, Prabowo J, Febyarto R, Rahayu, MSK, Damayanti E, Rimbawan, Sukandar D, Suryana Y, Irzaman, Alatas H. 2017. Proposed application of fast fourier transform in near infra red based non invasive blood glucose monitoring system. IOP Conference Series: Earth and Environmental Science 58: 012011.
14) Robiah S, Jenie RP, Dahrul M, Nurdin NM, Iskandar J, Kurniawan A, Rustami E, Syaifutra H, Alatas H, Irzaman, Damayanti E, Rimbawan, Sukandar D, Evriyanti, Budiarti S. 2017. Infra red light emitting diode in 1200 nm range have moderate performance in detecting glucose in human blood glucose model. IOP Conference Series: Earth and Environmental Science 58: 012021.
15) Jenie RP, Damayanti E, Sukandar D, Alatas, H, et al. 2018. Fast fourier transformed twin table ladder modulation on recognising non invasive blood glucose level measurement optical device spectral responses. IOP Conference Series: Earth and Environmental Science 187: 012012.
16) Jenie RP, Izraman HS, Nurdin NM. 2017. Multi formulated regression slightly outperform back propagation artificial neural network on recognising Gaussian randomized two dimensional data as blood glucose level non invasive measurement model. Prosiding Seminar Nasional Fisika (E-Journal) 6.
17) Tolimieri R, An M, Lu C. 2013. Algorithms for discrete Fourier transform and convolution. Springer Science &
Sensitivity and Specificity of Non-Invasive Blood Glucose Level

18) FANN 2015. Fast Artificial Neural Network Library (FANN). Available at: http://leenissen.dk/fann/wp/. Accessed on 25 December 2015.

19) Cherry AL, Dillon ME. 2013. The AC-OK cooccurring screen: Reliability, convergent validity, sensitivity, and specificity. J Addiction 2013: 1–8.

20) Stevenson M, Nunes T, Sanchez J, Thornton R, Reiczigel J. Robison-Cox J, Sebastiani P. 2012. epiR: An R package for the analysis of epidemiological data. R package version 0.9-43.

21) Racine JS. 2012. RStudio: A platform-independent IDE for R and sweave: SOFTWARE REVIEW. J Appl Econ 27: 167–172.

22) Hardin DS, Anderson W, Cattet J. 2015. Dogs can be successfully trained to alert to hypoglycemia samples from patients with type 1 diabetes. Diabetes Ther 6: 509–517.

23) Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. 2016. Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children. J Pediatr 168: 212–219.

24) Sakakibara A, Hashimoto Y, Kawakita R, Hosokawa Y, Nagahara K, Hasegawa Y, Hoshino S, Nagasaka H, Yorifuji T. 2018. Diagnosis of congenital hyperinsulinism: Biochemical profiles during hypoglycemia. Pediatr Diabetes 19: 259–264.

25) Klimontov VV, Myakina NE. 2017. Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. Diabetes Metab Syndr 11: 119–124.

26) Lee CJ, Wood GC, Bressler N, Govina T, Lazo M, Brown TT, Clark JM, Still C, Benotti P. 2019. Validation of the use of electronic medical records for identification of post-gastric bypass hypoglycemia cases. Obes Surg 29: 2126–2131.

27) Chen J, Lator J, Liu W, Druhl E, Granillo E, Vimalananda VG, Yu H. 2019. Detecting hypoglycemia incidents reported in patients’ secure messages: Using cost-sensitive learning and oversampling to reduce data imbalance. J Med Internet Res 21: e11990.

28) Eljil KS, Qadah G, Pasquier M. 2016. Predicting hypoglycemia in diabetic patients using time-sensitive artificial neural networks: Int J Healthc Inf Syst Inform 11: 70–88.

29) Ling SH, San PP, Nguyen HT. 2016. Non-invasive hypoglycemia monitoring system using extreme learning machine for Type 1 diabetes. ISA Trans 64: 440–446.

30) San PP, Ling SH, Nguyen HT. 2016. Deep learning framework for detection of hypoglycemic episodes in children with type 1 diabetes. In 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), pp. 3503–3506. IEEE, Orlando FL, USA.

31) Rivers KL, et al. 2015. Comparison between the oral glucose tolerance test and the Hba1c assay for detecting impaired glucose regulation in Bahamian adolescents. J Diabetes Metab 6: 3.

32) Hjellestad ID, Astor MC, Nilsen RM, Softeland E, Jonung T. 2013. HbA1c versus oral glucose tolerance test as a method to diagnose diabetes mellitus in vascular surgery patients. Cardiovasc Diabetol 12: 79.